Translational Cancer Research - Message from the Editor-in-Chief
It is my great pleasure to present to you the inaugural issue of Translational Cancer Research (TCR). This is an international peer-reviewed journal that aims to promote a rapid exchange of scientific information between clinicians and scientists worldwide. The Director of US National Institutes of Health (NIH), Dr. Francis Collins, proposed a new initiative of five thematic areas in 2010, and “Translating Basic Science Discoveries into New and Better Treatments” was one of those five thematic areas. Furthermore, NIH created its newest National Center for Advancing Translational Sciences (NCATS) on December 23, 2011. There is no doubt that advancing translational sciences have become an important mission of NIH. By leveraging findings from basic research, innovative methods and technologies as well as new targets can be developed for potential clinical applications of diagnostics and therapeutics in various cancers. Therefore, this new open access journal promises to make a significant impact upon the field of translation cancer research, publishing data of novel research investigations which bridge the laboratory and clinical settings including risk assessment, cellular and molecular characterization, prevention, detection, diagnosis and treatment of human cancers with the overall goal of improving the clinical care of cancer patients.
TCR is aiming to provide a forum for the dissemination of translational cancer research with a focus on cutting edge findings in this emerging field while providing up-to-date information on clinical trials related to cancer diagnosis, prevention, and treatment. TCR exerts to report the most recent advances in translational cancer research. TCR will accept manuscripts in the following categories which include: ORIGINAL ARTICLES, INVITED REVIEWS, MINI REVIEWS, RESEARCH HIGHLIGHTS, OPINION, PERSPECTIVES, COMMENTARIES, EDITORIALS, CLINICAL GUIDELINES, TECHNICAL NOTES, CASE REPORTS, BRIEF REPORT, and LETTERS TO THE EDITOR. In this first issue of TCR, there are 10 articles including three editorials, one original article, three review articles, one perspective, and two research highlights. In particular, several Program Directors of US National Cancer Institute (NCI) wrote an excellent review article to address a very important issue of radiotherapy in cancer treatment.
TCR is published bimonthly by Pioneer Bioscience Publishing Company (PBPC) and all articles can be submitted electronically online. Since PBPC is currently managing several top quality journals, I am sure that the online system of TCR manuscript submission and review will be straightforward and user-friendly. Our goal is to provide a prompt and efficient environment for scientific publications with outstanding editorial support. We hope the reader of TCR will enjoy a new, well constructed, and very informative journal.
I am honored to serve as the first Editor-in-Chief of Translational Cancer Research, and very grateful to have a team of excellent scientists and physicians joining the editorial board. Their diverse experiences enable our editorial team to lend their expertise to a broad spectrum of different cancer subjects. We promise to work together seamlessly, and I am confident that TCR will continue to publish high quality papers and become a leading journal in the field of cancer research with emphasis on translational sciences. Finally, I want to thank each of our contributors for sharing their research as well as knowledge and expertise to generate this eminent issue of TCR. It demonstrates a good beginning of TCR. Of course, your future support and nurture on TCR would be greatly appreciated.
Acknowledgments
Funding: None.
Footnote
Provenance and Peer Review: This article was commissioned by the Editorial Office, Translational Cancer Research. The article did not undergo external peer review.
Conflicts of Interest: The author has completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.3978/j.issn.2218-676X.2012.05.07). EYC serves as the Editor-in-Chief of Translational Cancer Research. The author has no other conflicts of interest to declare.
Ethical Statement: The author is accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.
Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/.
